Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00141531
Status:
COMPLETED
Last Update Posted:
2012-06-14
First Post:
2005-08-30
Brief Title:
Phase II Trial of EOquin in High-risk Superficial Bladder Cancer
Sponsor:
Spectrum Pharmaceuticals Inc
Organization:
Spectrum Pharmaceuticals Inc